Terada Norihiko, Itoh Naoya, Kurai Hanako
Division of Infectious Diseases Shizuoka Cancer Center Hospital Suntou-gun Japan.
J Gen Fam Med. 2020 Apr 10;21(4):127-133. doi: 10.1002/jgf2.320. eCollection 2020 Jul.
Recently, the spread of multidrug-resistant bacteria has become a global problem. Extended-spectrum beta-lactamase (ESBL)-producing (enterobacteria) is one example. The incidence of urinary tract infections caused by ESBL-producing enterobacteria has been increasing in some Japanese community settings. Currently, there is insufficient evidence on the effectiveness of oral antibiotics used for the treatment of pyelonephritis caused by ESBL-producing enterobacteria. We investigated the effectiveness of oral antibacterial agents against pyelonephritis caused by ESBL-producing .
The records of patients who had been treated for pyelonephritis caused by ESBL-producing enterobacteria with oral antibiotics between April 1, 2014, and March 31, 2019, were reviewed retrospectively to assess the effectiveness of oral antibiotic treatment.
A total of seven cases were identified, including 1 patient with a positive blood culture and one patient with a Pitt bacteremia score of four points, indicating that the infections were severe. The antibiotics used to treat pyelonephritis were amoxicillin-clavulanic acid (n = 3), minocycline (n = 1), levofloxacin (n = 3), and sulfamethoxazole-trimethoprim with amoxicillin-clavulanic acid (n = 1). None of the patients had recurrence of pyelonephritis in the 60 days following oral antibiotic treatment, and there were no deaths during the 60-day follow-up period.
These antibiotics should be considered for oral treatment of pyelonephritis caused by ESBL-producing enterobacteria. However, as there is insufficient evidence available on the effectiveness of these antibiotics for the management of ESBL-producing enterobacterial infections, further large-scale prospective studies are needed.
近年来,多重耐药菌的传播已成为一个全球性问题。产超广谱β-内酰胺酶(ESBL)的肠杆菌就是其中一例。在日本的一些社区环境中,由产ESBL肠杆菌引起的尿路感染发病率一直在上升。目前,关于用于治疗产ESBL肠杆菌引起的肾盂肾炎的口服抗生素有效性的证据不足。我们调查了口服抗菌药物对产ESBL肠杆菌引起的肾盂肾炎的有效性。
回顾性分析2014年4月1日至2019年3月31日期间接受口服抗生素治疗产ESBL肠杆菌引起的肾盂肾炎患者的记录,以评估口服抗生素治疗的有效性。
共确定7例病例,其中1例血培养阳性,1例皮特菌血症评分为4分,表明感染严重。用于治疗肾盂肾炎的抗生素为阿莫西林-克拉维酸(n = 3)、米诺环素(n = 1)、左氧氟沙星(n = 3)以及磺胺甲恶唑-甲氧苄啶联合阿莫西林-克拉维酸(n = 1)。口服抗生素治疗后60天内,所有患者均未出现肾盂肾炎复发,60天随访期内无死亡病例。
这些抗生素可考虑用于口服治疗产ESBL肠杆菌引起的肾盂肾炎。然而,由于关于这些抗生素治疗产ESBL肠杆菌感染有效性的证据不足,需要进一步开展大规模前瞻性研究。